ACON
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Aclarion, Inc.
- Nom
- Aclarion, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Information Services
- Bourse
- NASDAQ
- Capitalisation
- $5.6M
- Employés
- 11
- PDG
- Brent Ness
- Site web
- https://www.aclarion.com
- Marché
- BFRGBNBXCANFCMNDENSCKZIA
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 41 863 titres (~101 170,29 $ US)
- Insiders
- Williams Amanda MBond RyanWesemann WilliamNeal David KNess Brent
- Total bought
-
$101,170
Avg buy (VWAP, 90d window) $2.42 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-17
- Last synced
-
2026-08-23 00:12:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-17 | Williams Amanda M | Buy · P | 5,857 | $2.73 | $15,990 | Form 4 |
| 2026-08-14 | Gould Gregory A | Buy · P | 10,000 | $2.45 | $24,500 | Form 4 |
| 2026-08-13 | Bond Ryan | Buy · P | 21,122 | $2.37 | $50,059 | Form 4 |
| 2026-08-13 | Neal David K | Buy · P | 7,500 | $2.40 | $18,000 | Form 4 |
| 2026-08-13 | Ness Brent | Buy · P | 5,234 | $2.31 | $12,091 | Form 4 |
| 2026-08-13 | Wesemann William | Buy · P | 2,150 | $2.34 | $5,031 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 14.81 · operating margin -9313% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -291.3% | -183.8% | -0.4% | -8.0% | -14.7% | |
| Ebit Margin | -9551.9% | -14122.7% | -5706.7% | -9200.3% | -7420.2% | |
| Ebitda Margin | -9251.6% | -13700.3% | -5491.0% | -8962.7% | -7111.1% | |
| Operating Profit Margin | -9312.5% | -12057.2% | -6466.5% | -9201.2% | -4897.9% | |
| Pretax Profit Margin | -9551.9% | -15293.8% | -6513.4% | -11694.4% | -8210.5% | |
| Continuous Operations Profit Margin | -9551.9% | -15293.8% | -6513.4% | -11694.4% | -8210.5% | |
| Net Profit Margin | -9551.9% | -15293.8% | -6513.4% | -11694.4% | -8210.5% | |
| Bottom Line Profit Margin | -9560.7% | -15424.3% | -6513.4% | -12381.9% | -9878.4% | |
| Current Ratio | 14.806 | 0.715 | 0.404 | 2.470 | 0.096 | |
| Quick Ratio | 14.806 | 0.715 | 0.404 | 2.470 | 0.096 | |
| Solvency Ratio | -8.368 | -5.895 | -1.490 | -10.056 | -0.625 | |
| Cash Ratio | 14.351 | 0.393 | 0.320 | 2.139 | 0.057 | |
| Price To Earnings Ratio | -0.338 | -0.017 | -0.363 | -0.473 | -3.279 | |
| Price To Earnings Growth Ratio | 0.003 | 0.000 | 0.007 | -0.010 | -0.384 | |
| Forward Price To Earnings Growth Ratio | 0.003 | 0.000 | 0.007 | -0.010 | -0.384 | |
| Price To Earnings Diluted Ratio | -0.338 | -0.017 | -0.363 | -0.473 | -3.279 | |
| Price To Earnings Diluted Growth Ratio | 0.003 | 0.000 | 0.007 | -0.010 | -0.384 | |
| Price To Book Ratio | 0.191 | 0.127 | -2.448 | 1.591 | -3.409 | |
| Price To Sales Ratio | 32.317 | 2.686 | 23.630 | 58.586 | 323.946 | |
| Price To Free Cash Flow Ratio | -0.341 | -0.022 | -0.473 | -0.687 | -8.311 | |
| Price To Operating Cash Flow Ratio | -0.342 | -0.023 | -0.489 | -0.716 | -8.311 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.458 | 0.000 | 1.059 | |
| Debt To Equity Ratio | 0.000 | 0.000 | -1.546 | 0.000 | -0.349 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 2.830 | 0.000 | -0.536 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.065 | 2.189 | -3.379 | 1.309 | -0.330 | |
| Working Capital Turnover Ratio | 0.013 | -0.041 | -0.170 | -0.021 | -0.008 | |
| Operating Cash Flow Ratio | -8.556 | -4.570 | -1.144 | -7.186 | -0.308 | |
| Operating Cash Flow Sales Ratio | -94.602 | -115.292 | -48.365 | -81.879 | -38.976 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.061 | 1.033 | 1.042 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | -11.699 | -2.388 | -3.594 | -1.731 | |
| Interest Coverage Ratio | 0.000 | -10.296 | -8.016 | -3.689 | -6.198 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -3.240 | 0.000 | -1.175 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -3.240 | 0.000 | -1.175 | |
| Capital Expenditure Coverage Ratio | -332.816 | -16.375 | -30.513 | -23.695 | -2,349,949.000 | |
| Dividend Paid And Capex Coverage Ratio | -332.816 | -16.375 | -30.513 | -23.695 | -2,349,949.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 1.366 | 0.053 | -0.456 | -0.382 | -4.921 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -291.3% | ▼-107.5% | ▼-191.6% |
| Ebit Margin | -9551.9% | ▲4570.8% | ▼-351.5% |
| Ebitda Margin | -9251.6% | ▲4448.7% | ▼-348.2% |
| Operating Profit Margin | -9312.6% | ▲2744.7% | ▼-925.5% |
| Pretax Profit Margin | -9551.9% | ▲5741.9% | ▲700.9% |
| Continuous Operations Profit Margin | -9551.9% | ▲5741.9% | ▲700.9% |
| Net Profit Margin | -9551.9% | ▲5741.9% | ▲700.9% |
| Bottom Line Profit Margin | -9560.7% | ▲5863.6% | ▲1191.1% |
| Current Ratio | 14.806 | ▲14.091 | ▲11.108 |
| Quick Ratio | 14.806 | ▲14.091 | ▲11.108 |
| Solvency Ratio | -8.368 | ▼-2.473 | ▼-3.081 |
| Cash Ratio | 14.351 | ▲13.957 | ▲10.899 |
| Price To Earnings Ratio | -0.338 | ▼-0.321 | ▲0.556 |
| Price To Earnings Growth Ratio | 0.003 | ▲0.003 | ▲0.080 |
| Forward Price To Earnings Growth Ratio | 0.003 | ▲0.003 | ▲0.080 |
| Price To Earnings Diluted Ratio | -0.338 | ▼-0.321 | ▲0.556 |
| Price To Earnings Diluted Growth Ratio | 0.003 | ▲0.003 | ▲0.080 |
| Price To Book Ratio | 0.191 | ▲0.064 | ▲0.980 |
| Price To Sales Ratio | 32.317 | ▲29.631 | ▼-55.916 |
| Price To Free Cash Flow Ratio | -0.341 | ▼-0.319 | ▲1.626 |
| Price To Operating Cash Flow Ratio | -0.342 | ▼-0.318 | ▲1.635 |
| Debt To Assets Ratio | 0.000 | 0.000 | ▼-0.303 |
| Debt To Equity Ratio | 0.000 | 0.000 | ▲0.379 |
| Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.459 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.065 | ▼-1.124 | ▲0.894 |
| Working Capital Turnover Ratio | 0.013 | ▲0.054 | ▲0.059 |
| Operating Cash Flow Ratio | -8.556 | ▼-3.986 | ▼-4.203 |
| Operating Cash Flow Sales Ratio | -94.602 | ▲20.690 | ▼-18.779 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▼-0.058 | ▼-0.025 |
| Debt Service Coverage Ratio | 0.000 | ▲11.699 | ▲3.882 |
| Interest Coverage Ratio | 0.000 | ▲10.296 | ▲5.640 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲0.883 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲0.883 |
| Capital Expenditure Coverage Ratio | -332.816 | ▼-316.442 | ▲469737.663 |
| Dividend Paid And Capex Coverage Ratio | -332.816 | ▼-316.442 | ▲469737.663 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 1.366 | ▲1.313 | ▲2.234 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.4M | $123K | $1.8M | $3.5M | $19.5M | |
| Enterprise value | -$9.6M | -$331K | $1.9M | $2.1M | $21.1M | |
| EV / Sales | -126.35x | -7.24x | 25.02x | 34.22x | 349.94x | |
| EV / Op. cash flow | 1.34x | 0.06x | -0.52x | -0.42x | -8.98x | |
| EV / Free cash flow | 1.33x | 0.06x | -0.50x | -0.40x | -8.98x | |
| EV / EBITDA | 1.37x | 0.05x | -0.46x | -0.38x | -4.92x | |
| Net debt / EBITDA | 1.72x | 0.07x | -0.03x | 0.27x | -0.37x | |
| Current ratio | 14.81x | 0.71x | 0.40x | 2.47x | 0.10x | |
| Income quality | 0.99x | 0.75x | 0.74x | 0.70x | 0.47x | |
| Graham net-net | $21 | -$728 | -$35K | $19K | -$145K | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 108.3% | 114.1% | 127.1% | 110.7% | |
| Working capital | $11.6M | -$329K | -$1.9M | $1.0M | -$6.9M | |
| Invested capital | $12.8M | $970K | -$728K | $2.2M | -$5.7M | |
| Return on assets | -52.9% | -329.3% | -199.7% | -242.5% | -262.0% | |
| Operating ROA | -89.3% | -240.6% | -181.5% | -231.5% | -185.7% | |
| Return on tangible assets | -58.2% | -842.7% | -380.4% | -414.7% | -664.6% | |
| Return on equity | -56.4% | -720.9% | 674.6% | -317.6% | 86.4% | |
| Return on invested capital | -54.9% | -568.3% | -1226.0% | -249.9% | 79.2% | |
| Return on capital employed | -54.9% | -568.3% | 669.8% | -249.9% | 51.5% | |
| Earnings yield | -295.6% | -5694.4% | -275.6% | -199.6% | -25.3% | |
| Free cash flow yield | -293.6% | -4554.9% | -211.4% | -145.7% | -12.0% | |
| Capex / Op. cash flow | -0.3% | -6.1% | -3.3% | -4.2% | -0.0% | |
| Capex / Depreciation | 9.5% | 166.7% | 73.5% | 145.4% | 0.0% | |
| Capex / Sales | 28.4% | 704.1% | 158.5% | 345.6% | 0.0% | |
| SG&A / Sales | 7956463752.8% | 10028.3% | 5307.8% | 7426.2% | 3576.4% | |
| R&D / Sales | 1365098375.8% | 1943.8% | 1158.2% | 1766.9% | 1306.7% | |
| Stock comp / Sales | 139.1% | 628.7% | 604.7% | 2132.0% | 294.4% | |
| Intangibles / Total assets | 9.2% | 60.9% | 47.5% | 41.5% | 60.6% | |
| Days sales outstanding | 143d | 146d | 65d | 113d | 38d | |
| Days payables outstanding | 400d | 1495d | 3666d | 2558d | 5591d | |
| Operating cycle | 143d | 146d | 65d | 113d | 38d | |
| Cash conversion cycle | -257d | -1349d | -3601d | -2445d | -5553d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+1892.9%EV / Sales ▼-1646.1%EV / EBITDA ▲+2485.8%EV / Op. cash flow ▲+1.273Earnings yield ▲+53.989
Profitability
Return on equity ▲+6.645Return on assets ▲+2.764Return on invested capital ▲+5.134Return on capital employed ▲+5.134Operating ROA ▲+1.513Income quality ▲+0.237Tax burden 0.000
Efficiency
Days sales outstanding ▼-3.240Days payables outstanding ▼-1095.567Operating cycle ▼-3.240Cash conversion cycle ▲+1092.327Capex / Sales ▼-6.757R&D / Sales ▲+13650964.320
Balance-sheet strength
Current ratio ▲+14.091Net debt / EBITDA ▲+1.643Working capital ▲+11888564.000Invested capital ▲+11865060.000Intangibles / Total assets ▼-0.518
Change over 5 years
Valuation
Market cap ▼-87.5%EV / Sales ▼-136.1%EV / EBITDA ▲+127.8%EV / Op. cash flow ▲+10.314Earnings yield ▼-2.702
Profitability
Return on equity ▼-1.428Return on assets ▲+2.091Return on invested capital ▼-1.341Return on capital employed ▼-1.065Operating ROA ▲+0.964Income quality ▲+0.516Tax burden 0.000
Efficiency
Days sales outstanding ▲+105.032Days payables outstanding ▼-5190.975Operating cycle ▲+105.032Cash conversion cycle ▲+5296.007Capex / Sales ▲+0.284R&D / Sales ▲+13650970.691
Balance-sheet strength
Current ratio ▲+14.710Net debt / EBITDA ▲+2.081Working capital ▲+18445997.000Invested capital ▲+18564436.000Intangibles / Total assets ▼-0.514
Employee count
Peer market caps
Recent news
- 2026-08-20 Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site PR Audio: BROOMFIELD, Colo., August 20, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
- 2026-08-20 Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan''s ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the University of Arizona College of Medicine - Phoenix as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.
- 2026-08-12 Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan''s MR Spectroscopy (MRS) Scan Process BROOMFIELD, Colo., August 12, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
- 2026-08-12 Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan''s MR Spectroscopy (MRS) Scan Process Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion''s IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application titled “Multi-Voxel Prescription for Lumbar Disc Evaluation.
- 2026-08-06 Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.
- 2026-08-04 Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology PR Audio: BROOMFIELD, Colo., August 04, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
- 2026-08-04 Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology Partnership brings Nociscan for chronic low back pain to one of the nation''s leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company''s focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.
- 2026-07-29 Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 PR Audio: Broomfield, CO, July 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
- 2026-07-29 Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S. Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide Strong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company''s recent momentum and value creating priorities through the first half of 2026.
- 2026-07-21 Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan''s Growing Role in Real-World Clinical Practice PR Audio: BROOMFIELD, Colo., July 21, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.